RT @Ozymand36063774: @Sanctuary_Bio @Biohazard3737

RT @PCM_bio: I don’t really have a dog in the $srpt fight. Never thought the DMD therapies worked, so have stayed away from the stock and f….

RT @CloisterRes: Amazing - FDA also getting facts wrong!!. $SRPT

RT @Sanctuary_Bio: @monaco_biotech @adamfeuerstein I don't think highly of srpt mgmt but I actually disagree. What is the basis to stop for….

RT @bio_clouseau: $SRPT gets a platform tech designation on 6/4 for its AAVrh74 viral vector for LGMD 2E/R4 which seems to indicate the vir….

RT @JMaraganore: I’m sorry @Sarepta, this is just wrong!. IMO, our industry must always put patients first and we must be transparent to se….

RT @BioStocks: $SRPT Provides Statement on ELEVIDYS.

RT @RxRegA: Link:

RT @PersimmonTI: $NKTR. Seems like a bunch of betting (shares and calls) on anticipated ruling on motion for summary judgment…. Lack of sig….

RT @ScripMandy: $SRPT CEO Doug Ingram says the company did not believe the death in the limb girdle gene therapy trial of STP-9004 was mate….

RT @JohnCendpts: $SRPT down 36% today. Down 89% YTD. Buck stops at the CEO's desk. That's just the way it goes. Time for a change.

RT @JasonUkman: New @statnews op-ed: We are mothers of Duchenne patients. Recent setbacks with Sarepta Therapeutics must not stop progress.….

RT @edgeinvestor20: $SRPT I dont think the FDA asking them to stop shipping is real. The FDA already agreed to the black box warning and kn….

RT @Sanctuary_Bio: @bradloncar the biggest irony here is that he turned something that he thought was immaterial into the mother of all mat….

RT @matthewherper: Read this updated story on $srpt with comments from Peter Marks and ⁦@daphnezohar⁩ — by ⁦@adamfeuerstein⁩ and ⁦@Jasonmma….

RT @Sanctuary_Bio: If you haven't already I would encourage you to listen to from today, AF's comments regarding se….

@biotech1 @cngarabedian @SamFazeli8 @YaronWerber @adamfeuerstein @daphnezohar @JMaraganore @TimOpler @t_lorriman @ColonGraceE @bradloncar @LifeSciVC @mpreminger @MatteisPaul “I don’t want to say I’m optimistic, but I do think that the more of these headwinds that get behind us, the better off people are going to feel at the end of the day,” shares @cngarabedian, reflecting on the current biotech investment climate. “Public valuations have to be.

@biotech1 @cngarabedian @SamFazeli8 @YaronWerber @adamfeuerstein @daphnezohar @JMaraganore @TimOpler @t_lorriman @ColonGraceE @bradloncar @LifeSciVC @mpreminger @MatteisPaul “The number of deals involving the larger biopharmas taking out small guys was fewer than this time last year–12 deals in the first half–but the value was a lot higher,” shares @SamFazeli8 on the evolving M&A landscape. “We’re on a possible trajectory, if we get two or three.

@biotech1 @cngarabedian @SamFazeli8 @YaronWerber @adamfeuerstein @daphnezohar @JMaraganore @TimOpler @t_lorriman @ColonGraceE @bradloncar @LifeSciVC @mpreminger @MatteisPaul .@cngarabedian recaps a recent CEO forum including 80 executives from private and public companies across New York, Boston, San Francisco and D.C.: “They universally all walked away with a real feeling of encouragement and a real feeling that [the FDA] was listening, that they.

@biotech1 @cngarabedian @SamFazeli8 @YaronWerber @adamfeuerstein @daphnezohar @JMaraganore @TimOpler @t_lorriman @ColonGraceE @bradloncar @LifeSciVC @mpreminger @MatteisPaul Are there ways for the FDA and biotechs to work together and eliminate bureaucratic red tape that slows time to market? @adamfeuerstein points to the recent CRL for $RARE’s gene therapy for Sanfilippo syndrome, which was rejected over the number of thermometer probes in shipping.